BROKER FORECASTS
69

Most upside (3 months)

The Most Upside chart above shows the companies potential share price gain (%) (the potential share price increase from the current share to the broker target price)

  Company % change  
  AA Plc 64.87  
  Domino's Pizza Group PLC 51.57  
  IWG Plc 46.46  
  Ocado Group Plc 45.29  
  Nostrum Oil & Gas Plc 45.14  
  ITV PLC 44.32  
  Inmarsat PLC 41.49  
  Shire PLC 41.19  
  Kingfisher PLC 38.19  
  Sainsbury (J) PLC 37.16  
  Pearson PLC 36.17  
  Travis Perkins PLC 35.37  
  British American Tobacco PLC 32.29  
  Whitbread PLC 31.62  
  Barclays PLC 30.51  

Performance Analysis (6 Months)

The performance analysis chart above provides a detailed breakdown of Buy, Sell and Hold recommendations for the selected bank or stockbroker. To see a full explanation of how to use this chart, please visit the performance analysis explanation page.

Recommendation Summary (3 months)

Credit Suisse News

  • Broker views: Travel, mining and staffing

    14 August 2017 | TUI AG
    Equity analysts at Credit Suisse have moderated their investment rating on TUI (LON:TUI) and moved to a neutral rating (from underperform) believing the near-term risks faced by the travel operator...
  • AA downgraded by Credit Suisse

    08 August 2017 | AA
    Equity research analysts at Credit Suisse have downgraded their investment rating on AA (LON:AA.) to underperform (from neutral), which it says is due to the near-to-medium term challenges faced in...
  • Broker views: Mining and mobile payments

    26 July 2017 | Acacia Mining
    Credit Suisse has switched to a neutral stance on Acacia Mining (LON:ACA) - previously rated outperform - after reviewing the events since the export ban was imposed by the Tanzanian government,...
  • Hiscox downgraded by Credit Suisse

    18 July 2017 | Hiscox
    Credit Suisse has downgraded its recommendation on specialist insurer Hiscox (LON:HSX) to neutral (from outperform) following the recent strong share price performance and despite upping its target...
  • Broker views: Pharma and banking

    17 May 2017 | Hikma Pharmaceuticals
    Jefferies has double downgraded its investment rating on Hikma Pharmaceuticals (LON:HIK) and moved straight to underperform from buy, stating that the US Generics Advair delay is a significant...

Credit Suisse Notes